BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Singh A, Gupta V. SARS-CoV-2 therapeutics: how far do we stand from a remedy? Pharmacol Rep 2021;73:750-68. [PMID: 33389724 DOI: 10.1007/s43440-020-00204-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Franco JVA, Garegnani LI, Oltra GV, Metzendorf M, Trivisonno LF, Sgarbossa N, Ducks D, Heldt K, Mumm R, Barnes B, Scheidt-nave C. Short and Long-Term Wellbeing of Children following SARS-CoV-2 Infection: A Systematic Review. IJERPH 2022;19:14392. [DOI: 10.3390/ijerph192114392] [Reference Citation Analysis]
2 Sheikh M, Sheikh M, Samieefar N, Safari S. Factors Related to the Possibility of Accepting COVID-19 Vaccines: A Population-Based Cross-Sectional Study. Interv Pain Med Neuromod 2022;2. [DOI: 10.5812/ipmn-131019] [Reference Citation Analysis]
3 Shahanshah MFH, Anvitha D, Gupta V. In-silico screening to delineate novel antagonists to SARS-CoV-2 nucleocapsid protein. Physics and Chemistry of the Earth, Parts A/B/C 2022;127:103188. [DOI: 10.1016/j.pce.2022.103188] [Reference Citation Analysis]
4 Franco JVA, Garegnani LI, Oltra GV, Metzendorf M, Trivisonno LF, Sgarbossa N, Ducks D, Heldt K, Mumm R, Barnes B, Scheidt-nave C. Long-Term Health Symptoms and Sequelae Following SARS-CoV-2 Infection: An Evidence Map. IJERPH 2022;19:9915. [DOI: 10.3390/ijerph19169915] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Panayiotakopoulos GD, Papadimitriou DT. Rifampicin for COVID-19. World J Virol 2022; 11(2): 90-97 [DOI: 10.5501/wjv.v11.i2.90] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Shahanshah MFH, Jain S, Sharma B, Grewall A, Swami S. Comparative Analysis of B.1.617.2 (Delta) Variant of SARS-CoV-2. Journal of Microbiology and Infectious Diseases 2022. [DOI: 10.5799/jmid.1086226] [Reference Citation Analysis]
7 Örs ED, Alkan ŞB, Öksüz A. Possible Effect of Astaxanthin on Obesity-related Increased COVID-19 Infection Morbidity and Mortality. CNF 2022;18:265-73. [DOI: 10.2174/1573401317666211011105732] [Reference Citation Analysis]
8 Black SD. Molecular Modeling and Preliminary Clinical Data Suggesting Antiviral Activity for Chlorpheniramine (Chlorphenamine) Against COVID-19. Cureus 2022. [DOI: 10.7759/cureus.20980] [Reference Citation Analysis]
9 Chechetkin VR, Lobzin VV. Evolving ribonucleocapsid assembly/packaging signals in the genomes of the human and animal coronaviruses: targeting, transmission and evolution. J Biomol Struct Dyn 2021;:1-25. [PMID: 34338591 DOI: 10.1080/07391102.2021.1958061] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Cao Y, Xu X, Kitanovski S, Song L, Wang J, Hao P, Hoffmann D. Comprehensive Comparison of RNA-Seq Data of SARS-CoV-2, SARS-CoV and MERS-CoV Infections: Alternative Entry Routes and Innate Immune Responses. Front Immunol 2021;12:656433. [PMID: 34122413 DOI: 10.3389/fimmu.2021.656433] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
11 Garegnani LI, Madrid E, Meza N. Misleading clinical evidence and systematic reviews on ivermectin for COVID-19. BMJ Evid Based Med 2021:bmjebm-2021-111678. [PMID: 33888547 DOI: 10.1136/bmjebm-2021-111678] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 20.0] [Reference Citation Analysis]